000164429 001__ 164429
000164429 005__ 20240617134721.0
000164429 0247_ $$2doi$$a10.1016/S1474-4422(20)30238-6
000164429 0247_ $$2ISSN$$a1474-4422
000164429 0247_ $$2ISSN$$a1474-4465
000164429 0247_ $$2altmetric$$aaltmetric:90449688
000164429 0247_ $$2pmid$$apmid:32949547
000164429 037__ $$aDZNE-2022-00981
000164429 082__ $$a610
000164429 1001_ $$aLauwers, Elsa$$b0
000164429 245__ $$aPotential human transmission of amyloid β pathology: surveillance and risks
000164429 260__ $$aLondon$$bLancet Publ. Group$$c2020
000164429 3367_ $$2DRIVER$$aarticle
000164429 3367_ $$2DataCite$$aOutput Types/Journal article
000164429 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718624795_25688$$xReview Article
000164429 3367_ $$2BibTeX$$aARTICLE
000164429 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164429 3367_ $$00$$2EndNote$$aJournal Article
000164429 520__ $$aStudies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Although these data raise potential concerns for public health, convincing evidence for human iatrogenic transmission only exists for prions and amyloid β after systemic injections of contaminated growth hormone extracts or dura mater grafts derived from cadavers. Even though these procedures are now obsolete, some reports raise the possibility of iatrogenic transmission of amyloid β through putatively contaminated neurosurgical equipment. Iatrogenic transmission of amyloid β might lead to amyloid deposition in the brain parenchyma and blood vessel walls, potentially resulting in cerebral amyloid angiopathy after several decades. Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid β can also lead to Alzheimer's dementia. Large, long-term epidemiological studies and sensitive, cost-efficient tools to detect amyloid are needed to better understand any potential routes of amyloid β transmission and to clarify whether other similar proteopathic seeds, such as tau or α-synuclein, can also be transferred iatrogenically.
000164429 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000164429 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000164429 650_2 $$2MeSH$$aAlzheimer Disease: etiology
000164429 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000164429 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000164429 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000164429 650_2 $$2MeSH$$aAmyloid beta-Peptides: toxicity
000164429 650_2 $$2MeSH$$aAnimals
000164429 650_2 $$2MeSH$$aCreutzfeldt-Jakob Syndrome: metabolism
000164429 650_2 $$2MeSH$$aCreutzfeldt-Jakob Syndrome: pathology
000164429 650_2 $$2MeSH$$aCreutzfeldt-Jakob Syndrome: transmission
000164429 650_2 $$2MeSH$$aHumans
000164429 650_2 $$2MeSH$$aNeurodegenerative Diseases: etiology
000164429 650_2 $$2MeSH$$aNeurodegenerative Diseases: metabolism
000164429 650_2 $$2MeSH$$aNeurodegenerative Diseases: pathology
000164429 650_2 $$2MeSH$$aParkinson Disease: etiology
000164429 650_2 $$2MeSH$$aParkinson Disease: metabolism
000164429 650_2 $$2MeSH$$aParkinson Disease: pathology
000164429 650_2 $$2MeSH$$aPopulation Surveillance
000164429 650_2 $$2MeSH$$aRisk Factors
000164429 7001_ $$aLalli, Giovanna$$b1
000164429 7001_ $$aBrandner, Sebastian$$b2
000164429 7001_ $$aCollinge, John$$b3
000164429 7001_ $$aCompernolle, Veerle$$b4
000164429 7001_ $$aDuyckaerts, Charles$$b5
000164429 7001_ $$aEdgren, Gustaf$$b6
000164429 7001_ $$aHaïk, Stéphane$$b7
000164429 7001_ $$aHardy, John$$b8
000164429 7001_ $$aHelmy, Adel$$b9
000164429 7001_ $$aIvinson, Adrian J$$b10
000164429 7001_ $$aJaunmuktane, Zane$$b11
000164429 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b12$$udzne
000164429 7001_ $$aKnight, Richard$$b13
000164429 7001_ $$aLemmens, Robin$$b14
000164429 7001_ $$0P:(DE-HGF)0$$aLin, I-Chun$$b15
000164429 7001_ $$aLove, Seth$$b16
000164429 7001_ $$aMead, Simon$$b17
000164429 7001_ $$aPerry, V Hugh$$b18
000164429 7001_ $$aPickett, James$$b19
000164429 7001_ $$aPoppy, Guy$$b20
000164429 7001_ $$aRadford, Sheena E$$b21
000164429 7001_ $$aRousseau, Frederic$$b22
000164429 7001_ $$aRoutledge, Carol$$b23
000164429 7001_ $$aSchiavo, Giampietro$$b24
000164429 7001_ $$aSchymkowitz, Joost$$b25
000164429 7001_ $$aSelkoe, Dennis J$$b26
000164429 7001_ $$aSmith, Colin$$b27
000164429 7001_ $$aThal, Dietmar R$$b28
000164429 7001_ $$aTheys, Tom$$b29
000164429 7001_ $$aTiberghien, Pierre$$b30
000164429 7001_ $$avan den Burg, Peter$$b31
000164429 7001_ $$aVandekerckhove, Philippe$$b32
000164429 7001_ $$aWalton, Clare$$b33
000164429 7001_ $$aZaaijer, Hans L$$b34
000164429 7001_ $$aZetterberg, Henrik$$b35
000164429 7001_ $$aDe Strooper, Bart$$b36
000164429 773__ $$0PERI:(DE-600)2079704-7$$a10.1016/S1474-4422(20)30238-6$$gVol. 19, no. 10, p. 872 - 878$$n10$$p872 - 878$$tThe lancet <London> / Neurology$$v19$$x1474-4422$$y2020
000164429 8564_ $$uhttps://pub.dzne.de/record/164429/files/DZNE-2022-00981_Restricted.pdf
000164429 8564_ $$uhttps://pub.dzne.de/record/164429/files/DZNE-2022-00981_Restricted.pdf?subformat=pdfa$$xpdfa
000164429 909CO $$ooai:pub.dzne.de:164429$$pVDB
000164429 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000164429 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000164429 9141_ $$y2020
000164429 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000164429 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000164429 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET NEUROL : 2021$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000164429 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bLANCET NEUROL : 2021$$d2022-11-09
000164429 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000164429 980__ $$ajournal
000164429 980__ $$aVDB
000164429 980__ $$aI:(DE-2719)1210001
000164429 980__ $$aUNRESTRICTED